ANI PHARMACEUTICALS INC 8-K

What Happened

• ANI Pharmaceuticals, Inc. (ANIP) filed an 8-K reporting the results of its May 21, 2026 Annual Meeting of Stockholders. Stockholders elected seven directors, ratified Ernst & Young LLP as auditor, approved say-on-pay (advisory) and opted to hold future say-on-pay votes every one year, and approved the Company’s Amended and Restated 2022 Stock Incentive Plan.
• At the record date (March 23, 2026) there were 22,750,198 shares of Common Stock and 10,864 shares of Class C Special Stock outstanding (22,761,062 total votes). 16,926,047 votes were present virtually or by proxy, constituting a quorum.
• Directors elected (each to serve until 2027 annual meeting): Thomas Haughey; Nikhil Lalwani; Matthew J. Leonard, R.Ph.; Antonio R. Pera; Muthusamy Shanmugam; Renee P. Tannenbaum, Pharm.D.; Jeanne A. Thoma.

Key Details

• Amended 2022 Stock Incentive Plan: Approved by vote — For 13,806,050; Against 1,080,387; Abstain 9,388; Broker Non-Votes 2,030,222. The Amended plan is filed as Exhibit 10.1 to the 8-K.
• Say-on-pay (advisory): Approved — For 13,819,988; Against 1,058,460; Abstain 17,377; Broker Non-Votes 2,030,222. Shareholders voted to hold future advisory votes on executive compensation every one year (For: 14,412,299).
• Ratification of independent auditor: Ernst & Young LLP ratified — For 16,874,103; Against 7,333; Abstain 44,611.
• Director election votes (examples): Thomas Haughey — For 14,732,894; Nikhil Lalwani — For 14,873,796 (other nominees received similar affirmative vote totals).

Why It Matters

• Approval of the Amended 2022 Stock Incentive Plan creates or modifies the company’s equity award program, which may affect future equity grants and potential dilution for existing shareholders—investors should review the plan text (Exhibit 10.1) for details on share pool and award types.
• Re-election of the full board and ratification of the auditor signal continuity of governance and financial reporting relationships for fiscal 2026.
• The advisory approval of executive compensation and the decision to hold say-on-pay votes annually provide recurring investor feedback on pay practices; the vote totals show meaningful opposition (over 1 million “Against” votes on pay and over 1 million against the stock plan), which some investors may monitor for governance implications.